30
CARDIOVASCULAR
hamburger

Xience™ Stent Evidence

XIENCE™ Stent is the DES that delivers consistently outstanding short- and long-term patient outcomes.2

In fact XIENCE™ Stent consistently has the lowest rate of late and very late stent thrombosis (ST)—not only a year but a decade after the intervention—providing evidence that the XIENCE™ Stent's unparalleled patient outcomes last far beyond the intervention.1
 

Exceptional Long-Term Patient Data

XIENCE™ Stent’s Consistently Low Rates of Late and Very Late Stent Thrombosis1

XIENCE Stent showed consistently low stent thrombosis rates of 0% at 1-5 years, and in many patients types, including complex patients
XIENCE Stent showed consistently low stent thrombosis rates of 0% at 1-5 years, and in many patients types, including complex patients
XIENCE Stent had only 0.8% stent thrombosis at 10 years

7-Year TLR Data

Long-term restenosis rates are also low, as shown by freedom from clinically driven target lesion revascularization (CD-TLR) at 7 years.9

93% of patients were free from target lesion revascularization 7 years after the XIENCE Stent implant

Optimal Device Success

XIENCE™ Stent data shows consistent device success—and in all types of patients and lesions.

XIENCE Stent data reveal a 99% acute success rate, showing optimal device success

Improved Quality of Life with XIENCE™ Stent11

XIENCE™ Stent has been shown to improve patient quality of life out to 3 years with 80% of patients reporting that they were angina free.


See the long-term results in complex patients treated with XIENCE™ Stent.

Improved QOL at 3 Years11

70% of patients had no angina symptoms 3 years after XIENCE Stent implant

  • Manuals & Technical Resources
  • Cardiovascular Products
  • Customer Service

References

  1. Zanchin C, et al. JACC Cardiovasc Interv. 2019;12(17):1665-1675. Serruys P, et al. N Engl J Med. 2010;363:136-146. Shiomi H, et al. JACC Cardiovasc Interv. 2019;12:637-647. Kufner S, et al. Circulation. 2019:139(3):325-333. Palmerini T, et al. Lancet. 2013;379:1393-1402. Bangalore S, et al. Circulation. 2012;125:2873-2891. Bangalore S, et al. Circ Cardiovasc Interv. 2013;6(6):378-390. Pilgrim T, et al. Lancet. 2014;384:2111-2122. Pilgrim T, et al. Lancet. 2018;392:737-746. Data on file at Abbott.
  2. Zanchin C. et al. JACC Cardiovasc Interv. 2019;12(17):1665-1675. Serruys P, et al. N Engl J Med. 2010;363:136-146. Shiomi H, et al. JACC Cardiovasc Interv. 2019;12:637-647. Kufner S, et al. Circulation. 2019:139(3):325-333.
  3. Mehran R, et al. TCT Connect - XIENCE 28/90.
  4. Von Birgele C, et al. J Am Coll Cardiol. 2012;59(15):1350-1361.
  5. Van Geuns RJ, et al. TCT 2019, IDEAL-LM.
  6. Chevalier B, et al. EuroIntervention. 2018;13(13):1561-1564.
  7. Gao R, et al. TCT 2019, ABSORB China.
  8. Kufner S, et al. Circulation. 2019:139(3):325-333.
  9. Shiomi H, et al. JACC Cardiovasc Interv. 2019;12(7):637-647.
  10. Saito S, et al. Eur Heart J. 2014;35:2021-2031. Saito S, et al. EuroIntervention. 2019;15(11):e1006-e1013. Natsuaki M, et al. J Am Coll Cardiol. 2013;62(3):181-190. Stone G, et al. Lancet. 2018:392:1530-40.
    Note: 99% was the lowest device success rate.
  11. Baron SJ, et al. J Am Coll Cardiol. 2017;70(25):3113-3122.

MAT-2101782 v1.0

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.

False
accessibility
© 2016 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

accessibility

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.